Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Sickle Cell Disease and Treatment

The Sickle Cell Disease Channel on VJHemOnc is supported by Agios Pharmaceuticals The supporter has no influence over the production of the content.

View overview page
2:20
The evolving treatment landscape of SCD
Clark Brown • 24 Jun 2022
2:16
GBT021601, a next generation HbS polymerization inhibitor for the treatment of SCD
Clark Brown • 24 Jun 2022
1:36
Incentive spirometry to prevent acute chest syndrome in adults with SCD
Anita Rijneveld • 20 Jun 2022
1:06
Unmet needs in SCD: the need for improved therapies and combination approaches
Santosh Saraf • 21 Jun 2022
0:59
The safety and efficacy of etavopivat in SCD
Santosh Saraf • 21 Jun 2022
7:39
CLIMB THAL-111 and CLIMB SCD-121: exa-cel gene therapy in TDT and SCD
Franco Locatelli • 11 Jun 2022
1:21
The use of radiomics and artificial intelligence for sickle cell disease
Raffaella Colombatti • 11 Jun 2022
1:45
Towards a personalized treatment approach for SCD
Raffaella Colombatti • 11 Jun 2022
3:43
Targeting oxidative stress in beta-thalassemia and SCD
Maria Domenica Cappellini • 10 Jun 2022
0:52
Challenges of in vivo gene editing for diseases of the hematopoietic system
Agnieszka Czechowicz • 25 Apr 2022
3:15
How novel agents are transforming the treatment landscape of SCD
Subarna Chakravorty • 4 Apr 2022
1:37
Health inequalities in red cell disorders
Subarna Chakravorty • 4 Apr 2022
1:35
The mechanism of action of hydroxyurea in SCD
Andreas Kulozik • 24 Apr 2022
1:35
Unmet needs in sickle cell disease
Josh Wright • 4 Apr 2022
4:07
Current and future treatment of SCD
Josh Wright • 4 Apr 2022
1:16
Adult stem cell transplantation for the treatment of SCD
Josh Wright • 4 Apr 2022

The Sickle Cell Disease Channel on VJHemOnc is supported by Agios Pharmaceuticals

The supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The Non-Malignant Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals